COVID-19 related demand helped Repligen in Q3 with the emerging gene therapy sector also providing a revenue boost. The processing technology firm’s revenue reached $94.1 million for the three months ended September 30, up 35% year-on-year. Gross profits also increased, climbing 40% to $54.5 million. Repligen attributed the gains to increased demand for its technologies from companies working on SARS-CoV-2 vaccines or related therapeutics. CEO Tony Hunt told analysts “We estimate that COVID programs accounted for approximately 55% of our…